Industry Development Partner
NEC OncoImmunity is a bioinformatics company offering proprietary machine-learning based software to address the key knowledge gaps in the prediction of bone fide immunogenic neoantigens for personalized cancer immunotherapy. NEC OncoImmunity is dedicated to develop software solutions that facilitate effective patient selection for cancer immunotherapy, and identify optimal neoantigen targets for truly personalised cancer vaccines & cell therapies in clinically actionable time-frame.
Adaptive Biotechnologies is a pioneer in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. Adaptive Therapeutics’ platform allows the discovery of potent, ultra-low frequency TCRs with differentiated therapeutic potential. This TruTCRTM engine combines Adaptive’s foundational immunosequencing platform with a multiplex approach to map TCRs to antigens at high specificity plus pairSEQTM to accurately pair TCR alpha/beta chains. Adaptive has discovered and is validating candidate TCRs with superior cytolytic activity in oncology.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).
The PolyPeptide Group employs approximately 750 staff at sites in Belgium, France, India, Sweden and the USA. The PolyPeptide Group is the world’s largest independent contract manufacturer of therapeutic peptides. The privately-held organization manufactures over one third of all approved peptide drug substances and accounts for over 30% of the sales of outsourced peptide therapeutics worldwide. The Group offers its customers an almost unprecedented long-term security of supply with six GMP facilities worldwide and an exclusive focus on pharmaceutical peptide manufacture.
Shenzhen Yuce Biotechnology (Yucebio) is a leading biotech company in China, focusing on neoantigen based tumor immune diagnosis and treatment. We provide a comprehensive solution for clinical unmet need and for potential drug target discovery. Yucebio is a member of TESLA (Tumor Epitope SeLection Alliance), our vision is making cancer immunotherapies more effective!
IOVaxis is an immunoncology company dedicated to research and development of neoantigen-based cancer immunotherapy including personalized therapeutic cancer vaccines. We are looking for clinical partners for our therapeutic cancer vaccines based on our “NeoCure” and “NeoReady” platforms.
The Liberty PRIME is the absolute best system available for synthesizing peptides for personalized medicine. The system is cGMP compliant with unmatched purity, speed, and efficiency for peptide production in batch quantities. No other peptide synthesizer even comes close to the PRIME’s incredibly fast cycle times, with absolute minimum waste production. CEM Corporation has pioneered the use of microwave technology for peptide production since 2004 and remains the market leader in peptide synthesis instrumentation.
Gyros Protein Technologies AB is a leading provider of solutions for peptide synthesis and bioanalysis. Automated multi-channel peptide synthesizers from Gyros Protein Technologies are used in cGMP facilities for the rapid production of peptides for personalized medicine.
Our focus is on helping scientists in industry and academia to increase productivity in research, drug discovery, pre-clinical and clinical development. The company combines the nanoliter-scale immunoassay expertise of Gyros with over three decades of instrument manufacturing experience and scientific knowledge in peptide synthesis found in Protein Technologies.
Almac has been supplying peptides to the research community and for clinical trials for over 20 years. The field of personalized cancer vaccines requires a new manufacturing paradigm to ensure high throughput manufacture of multiple neoantigens in an appropriate timescale to the required quality and regulatory standards. Almac has created a unique offering to meet all of those demands, which can be tailored to meet specific client needs.
Ardigen brings together bioinformatics and Artificial Intelligence for the purpose of identification of immunogenic neoantigens and optimization of targets for cancer vaccines and adoptive cell therapies.
Our neoantigen prediction platform provides unique approach to the assessment of neoantigen’s potential to elicit immune response. Its effectiveness and other features, e.g. safety evaluation and off-target exclusion resulted in an invitation of Ardigen to the TESLA consortium.
For more information, visit www.ardigen.com
Bachem provides a full range of services to the pharma and biotech industries. It specializes in the development of innovative, efficient manufacturing processes and the reliable production of peptide-based active pharmaceutical ingredients. The group has a global reach with more experience and know-how than any other company in the industry. Towards its customers, Bachem shows total commitment to quality, innovation and partnership.
Bachem. Pioneering Partner for Peptides
BCN Peptides is completely focused on the cGMP manufacture of Bioactive Peptides for Pharmaceutical and Veterinary applications. We concentrate our efforts in the following activities:
• Synthesis of API Peptides.
• Production of Peptides for Personalized Medicine. Manufacturing of Small quantities of GMP Peptides devoted for a single patient. This is a new approach for API production, including GMP requirements and Regulatory requirements that require a new scenario for both Industry and Authorities.
Cayman Chemical’s Immunopeptidome Profiling Services enable efficient, cost-effective deep sequence analysis of MHC Class I and II associated peptides by LC-MS/MS, enabling neoantigen identification in cell lines and tumor tissue, and immunogenicity testing of biological therapeutics. Immunopeptidome Profiling is part of Cayman’s diverse suite of discovery services including medicinal chemistry, structure-based drug design, complex multi-step organic synthesis, analytical chemistry, bioanalysis, and custom assay development.
Leading provider of specialized immunology and proteomics services to the biopharmaceutical industry with laboratory facilities located globally. Caprion offers proprietary multiparametric flow cytometry for monitoring of immune responses and mass spectrometry services for quantitative and robust measurement of protein biomarkers across the drug development life cycle.
CPC Scientific is a globally recognized and leading CDMO specializing in synthetic peptide production. We work directly with leaders in the biotechnology and pharmaceutical industries to help bring life-changing therapeutics and diagnostics to market. We boast the largest GMP peptide facility in the world, which successfully has undergone multiple FDA inspections and audits by global pharma organizations. CPC Scientific has the capability of serving customers from early drug discovery stages through clinical trials to commercial manufacturing.
CreoSalus is a life-sciences company offering a broad range of services to the peptide, pharma and biotech industries. It is a unique peptide company in that it offers fine chemicals and raw materials for peptide production, cGMP Contract Manufacturing of peptide drug substances and sterile injection drug products, R&D to scale-up, peptide synthesizers, custom peptide synthesis and proprietary drugs and devices. CreoSalus is a quality focused, innovative and quick turnaround pharma partner.
Hypertrust patient data care provides unique blockchain-based solutions for secure handling of patient and other sensitive data.
The first application is the patient-centered closed-loop supply and distributed data chain for autologous cell therapies. With hypertrust X-Chain we created a next-generation solution enabling a safe, efficient and transparent exchange of data across the entire process of autologous cell therapies – with far-reaching benefits for pharma companies and all other stakeholders in the supply and data chain.
A critical factor facing the Cell Therapy industry is choosing technologies and partners that can deliver scale. There’s no other field of medicine that requires the level of mass customization of production and careful orchestration of production pathways that cell therapies demand. From sample collection through logistics, manufacturing and final transplantation, TrakCel’s proven technology integrates and orchestrates every aspect of your Autologous and Allogeneic supply chains in a scalable, compliant and validated technology platform.
Provepharm Life Solutions is a pharmaceutical and a CDMO company commercializing immunopeptide services since 2003.
Pionner in the chemical synthesis of + 100 mer long peptide we delivered our first clinical batch of a 96-mer peptide in 2006.
Specialized in microgram therapies we have developed a one-stop-shop offer for the delivery of ready to use peptide-based drug products including conjugates.
For personalized peptide vaccine programs we designed a GMP manufacturing process to deliver up to 40 neoantigens every 6 weeks.
Robust and efficient Quality Control testing is critical for the development of personalized cancer vaccines and immunotherapies in order to reduce time to market and improve patient outcomes.
Developers, producers need QC testing which help de-risk their product development pipeline by preventing adventitious agent contamination and cell lines misidentification.
To meet those objectives, PathoQuest offers advanced Next Generation Sequencing (NGS) solutions that supplement or replace traditional methods and support the strategic decision-making process. This innovative approach allows for robust and unambiguous level of testing and for faster turnaround time.